There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Representatives of Moderna Biotech UK and NHS England will also be questioned by the inquiry, led by crossbench peer Baroness ...

There is no antiviral treatment for the miserable but thankfully short-lived illness, and no vaccine—yet. But scientists at Moderna are in the late stages of testing what could be the first such ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

If he’s confirmed as health secretary, Robert F. Kennedy Jr. will have broad authority to pursue an anti-vaccine agenda.

Moderna (MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine. The company now expects $1.5 billion to $2 ...

But Moderna aims to make waves with its messenger RNA vaccine technology ... in the form of a single injection in the upper arm—or a placebo that doesn’t contain active ingredients.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business ...

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats CAMBRIDGE, MA / ACCESS ...